Dr. Reddy’s Laboratories Limited announced that its U.S. subsidiary, Dr. Reddy’s Laboratories Inc., has successfully sold all issued and outstanding membership interests in Dr. Reddy’s Laboratories Louisiana LLC. This sale includes its manufacturing facility in Shreveport, Louisiana, and was completed on March 21, 2025.
Following the transaction, Dr. Reddy’s Laboratories Louisiana LLC is no longer a wholly owned subsidiary of Dr. Reddy’s Laboratories Inc. or a step-down subsidiary of Dr. Reddy’s Laboratories Limited. This move aligns with the company’s strategic decisions in the U.S. pharmaceutical market.
Recently, Dr. Reddy’s Laboratories Ltd announced a recall of one batch (Lot No: A1540076) of Levetiracetam in 0.75% Sodium Chloride Injection (1,000 mg/100 mL) in the U.S.
The recall is due to a labelling error, where the infusion bag is mislabeled as Levetiracetam in 0.82% Sodium Chloride Injection (500 mg/100 mL), while the outer aluminium overwrap correctly identifies the product.
This recall is being conducted at the consumer level to ensure patient safety. Healthcare providers and consumers are advised to check packaging carefully and discontinue use of the affected lot if found.
Dr. Reddy’s Laboratories Ltd, a global pharmaceutical company headquartered in Hyderabad, India, was founded in 1984 with a commitment to providing affordable and innovative medicines. Guided by the purpose of “Good Health Can’t Wait,” the company offers a diverse portfolio, including APIs, generics, branded generics, biosimilars, and OTC products. Its key therapeutic areas include gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy’s serves major markets such as the USA, India, Russia & CIS countries, China, Brazil, and Europe, ensuring access to high-quality healthcare solutions worldwide.
On March 21, 2025, Dr. Reddy’s Laboratories share price (NSE: DRREDDY) opened at ₹1,190.20 and closed at ₹1,202.25, up by 1.27%. The stock price touched its day’s high at ₹1,204.65.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Mar 24, 2025, 9:25 AM IST
Nikitha Devi
Nikitha is a content creator with 6+ years of experience in the financial domain. Specialising in personal finance, investments, and market insights, Nikitha simplifies complex financial topics, making them accessible to readers.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
